BioCentury | Apr 3, 2020
Product Development

COVID-19: manufacturing mAbs in patients

The urgency and scale of the coronavirus outbreak could drive progress in an emerging therapeutic strategy suited to rapid development and distribution -- encoding of antibodies in RNA or DNA. Neutralizing mAbs against SARS-CoV-2 have...
BioCentury | Nov 22, 2019
Product Development

The quiet disrupters: DNA-encoded and RNA-encoded antibodies

A new approach to streamlining biologics manufacturing could soon catch on--encoding the therapies in DNA or RNA, which enjoins the patient to produce the proteins in vivo . While the biggest upside may be the speed...
BioCentury | Sep 1, 2017
Company News

ethris and AZ partner to develop respiratory mRNA therapies

ethris GmbH (Martinsried, Germany) partnered with AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit to develop mRNA therapies for respiratory diseases using ethris' stabilized non-immunogenic messenger RNA (SNIM-RNA) technology. ethris will receive €25 million...
BioCentury | Aug 21, 2017
Company News

ethris and AZ partner to develop respiratory mRNA therapies

ethris GmbH (Martinsried, Germany) partnered with AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit to develop mRNA therapies for respiratory diseases using ethris' stabilized non-immunogenic messenger RNA (SNIM-RNA) technology. ethris will receive €25 million...
BioCentury | Feb 25, 2017
Product Development

Getting the message

Hailed as a faster, cheaper way of producing therapeutic proteins than recombinant technologies, mRNA technologies have attracted some $2.5 billion from partnerships and investments from pharmas and VCs hoping to get in on the ground...
BioCentury | Jan 8, 2015
Product R&D

Shooting the messenger

Although mRNA-based therapies have caught people's attention in the last few years as vaccines for cancer or infectious diseases, two recent announcements suggest mRNA is gaining traction in protein replacement therapy, too. Silence Therapeutics plc...
BioCentury | May 20, 2013
Strategy

Let a thousand ideas bloom

Shire plc has long been a growth through acquisition company, but the pace of its external discovery is picking up steam and the company now has over 20 ongoing projects to show for it. Traditional...
BioCentury | Mar 25, 2013
Strategy

Platform propellant

In the richest upfront deal for early stage technology since the blockbuster Abbott-Reata partnership in 2011, AstraZeneca plc has provided Moderna Therapeutics Inc. with enough cash to mature the biotech's therapeutic mRNA technology and begin...
BioCentury | Jan 14, 2013
Company News

ethris, Shire deal

ethris and Shire partnered to develop and commercialize RNA-based therapies for protein replacement based on ethris' stable and non-immunogenic messenger RNA (SNIM-RNA) technology. The partners declined to disclose details. ethris GmbH , Martinsried, Germany Shire plc...
BioCentury | Feb 3, 2011
Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Chemically modified mRNA to induce expression of therapeutic proteins Chemically modified mRNA could induce the expression of therapeutic proteins. In healthy...
Items per page:
1 - 10 of 10
BioCentury | Apr 3, 2020
Product Development

COVID-19: manufacturing mAbs in patients

The urgency and scale of the coronavirus outbreak could drive progress in an emerging therapeutic strategy suited to rapid development and distribution -- encoding of antibodies in RNA or DNA. Neutralizing mAbs against SARS-CoV-2 have...
BioCentury | Nov 22, 2019
Product Development

The quiet disrupters: DNA-encoded and RNA-encoded antibodies

A new approach to streamlining biologics manufacturing could soon catch on--encoding the therapies in DNA or RNA, which enjoins the patient to produce the proteins in vivo . While the biggest upside may be the speed...
BioCentury | Sep 1, 2017
Company News

ethris and AZ partner to develop respiratory mRNA therapies

ethris GmbH (Martinsried, Germany) partnered with AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit to develop mRNA therapies for respiratory diseases using ethris' stabilized non-immunogenic messenger RNA (SNIM-RNA) technology. ethris will receive €25 million...
BioCentury | Aug 21, 2017
Company News

ethris and AZ partner to develop respiratory mRNA therapies

ethris GmbH (Martinsried, Germany) partnered with AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit to develop mRNA therapies for respiratory diseases using ethris' stabilized non-immunogenic messenger RNA (SNIM-RNA) technology. ethris will receive €25 million...
BioCentury | Feb 25, 2017
Product Development

Getting the message

Hailed as a faster, cheaper way of producing therapeutic proteins than recombinant technologies, mRNA technologies have attracted some $2.5 billion from partnerships and investments from pharmas and VCs hoping to get in on the ground...
BioCentury | Jan 8, 2015
Product R&D

Shooting the messenger

Although mRNA-based therapies have caught people's attention in the last few years as vaccines for cancer or infectious diseases, two recent announcements suggest mRNA is gaining traction in protein replacement therapy, too. Silence Therapeutics plc...
BioCentury | May 20, 2013
Strategy

Let a thousand ideas bloom

Shire plc has long been a growth through acquisition company, but the pace of its external discovery is picking up steam and the company now has over 20 ongoing projects to show for it. Traditional...
BioCentury | Mar 25, 2013
Strategy

Platform propellant

In the richest upfront deal for early stage technology since the blockbuster Abbott-Reata partnership in 2011, AstraZeneca plc has provided Moderna Therapeutics Inc. with enough cash to mature the biotech's therapeutic mRNA technology and begin...
BioCentury | Jan 14, 2013
Company News

ethris, Shire deal

ethris and Shire partnered to develop and commercialize RNA-based therapies for protein replacement based on ethris' stable and non-immunogenic messenger RNA (SNIM-RNA) technology. The partners declined to disclose details. ethris GmbH , Martinsried, Germany Shire plc...
BioCentury | Feb 3, 2011
Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Chemically modified mRNA to induce expression of therapeutic proteins Chemically modified mRNA could induce the expression of therapeutic proteins. In healthy...
Items per page:
1 - 10 of 10